When Does Ibrance Go Generic?

Generic versions of Ibrance reach the market when a manufacturer wins FDA approval of an Abbreviated New Drug Application (ANDA) proving bioequivalence to the brand. ANDA filers must address every Orange Book-listed patent; certifying that a patent is invalid or not infringed (a "Paragraph IV" certification) triggers Hatch-Waxman litigation and a 30-month FDA stay. The first filer to clear that gauntlet earns 180 days of generic exclusivity as the sole low-cost competitor — the period in which it captures the most margin before prices collapse. Because entry is blocked until the LATEST relevant patent clears (this portfolio runs to 2041), the practical generic date is usually later than the earliest expiration alone implies.

Because Ibrance's patent cliff is within three years, generic manufacturers are likely already preparing ANDA filings or have filed Paragraph IV certifications. Under Hatch-Waxman, the first successful Paragraph IV challenger earns a 180-day exclusivity period as the sole generic. Watch FDA's Paragraph IV certification list for filing activity tied to Ibrance.

Once generic Ibrance enters the market, brand prices historically fall 50–90% within two years as multiple ANDA holders compete. The single biggest drop typically arrives after the first filer's 180-day exclusivity ends and additional generics flood in. Patients should ask their pharmacist about generic substitution and compare cash prices on GoodRx and Mark Cuban's Cost Plus Drugs once a generic is approved.

The authoritative source for which generic versions are actually approved is the FDA Orange Book, which lists every ANDA-approved equivalent and the patents an applicant had to clear. To compare cash prices once a generic lands, check GoodRx and Mark Cuban's Cost Plus Drugs. Underlying patent expiration data on this page is sourced from USPTO PatentsView.

Ibrance is protected by 19 US patents — a large portfolio that signals an aggressive lifecycle management strategy. Mega-portfolios of 15+ patents are characteristic of top-selling drugs (Humira famously had over 130) where the manufacturer has built layered protection across composition, multiple formulations, dosing schedules, drug-device combinations, and method-of-use claims for individual indications. These layered portfolios typically face Paragraph IV litigation under the Hatch-Waxman framework as generic challengers test secondary patents one by one.

All 19 patents in the Ibrance portfolio are assigned to Pfizer Inc., indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.

The Ibrance portfolio scores 62/100 (Grade C, "moderate") on the PatentCliff Strength index. The strongest signal is portfolio size (100/100), and the weakest is technology diversity (23/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.

Looking at the 19 dated patents in the portfolio, the largest cluster (6 patents) falls in the "Beyond 2036" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.

The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.